November 5, 2009 – The Moscow Arbitration Court considered disputes between a big pharma company and the Russian PTO (another big pharma company Teva Corp. represented by Sojuzpatent was an interested party on the Russian PTO's side) on the previous invalidation of the Eurasian patent 4544 (related to Alendronate) and ruled in favor of Teva Corp.